Halozyme Therapeutics Inc. [HALO] Revenue clocked in at $180.50 million, up 56.51% YTD: What’s Next?

Must read

Halozyme Therapeutics Inc. [NASDAQ: HALO] stock went on an upward path that rose over 0.18% on Tuesday, amounting to a one-week price decrease of less than -4.29%. The company report on September 2, 2020 that Halozyme To Participate In 2020 Wells Fargo Virtual Healthcare Conference.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in the upcoming 2020 Wells Fargo Virtual Healthcare Conference. Dr. Torley will take part in a fireside chat at 10:00 a.m. ET / 07:00 a.m. PT on Wednesday, September 9, 2020.

A live webcast of the event can be accessed through the “Investors” section of Halozyme’s website (www.halozyme.com), and an archive will be made available for 90 days following the event. To access a live webcast, please visit Halozyme’s website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

Over the last 12 months, HALO stock rose by 74.86%. The one-year Halozyme Therapeutics Inc. stock forecast points to a potential upside of 16.42. The average equity rating for HALO stock is currently 2.30, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $3.78 billion, with 135.94 million shares outstanding and 131.63 million shares in the current float. Compared to the average trading volume of 1.12M shares, HALO stock reached a trading volume of 1279571 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Halozyme Therapeutics Inc. [HALO]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HALO shares is $33.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HALO stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Benchmark Company have made an estimate for Halozyme Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 01, 2020. While these analysts kept the previous recommendation, Piper Sandler raised their target price from $18 to $27. The new note on the price target was released on February 05, 2020, representing the official price target for Halozyme Therapeutics Inc. stock. Previously, the target price had yet another raise from $17 to $24, while BMO Capital Markets kept a Outperform rating on HALO stock.

The Average True Range (ATR) for Halozyme Therapeutics Inc. is set at 0.96, with the Price to Sales ratio for HALO stock in the period of the last 12 months amounting to 20.94. The Price to Book ratio for the last quarter was 35.58, with the Price to Cash per share for the same quarter was set at 2.83.

HALO Stock Performance Analysis:

Halozyme Therapeutics Inc. [HALO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.29. With this latest performance, HALO shares dropped by -4.21% in over the last four-week period, additionally plugging by 42.82% over the last 6 months – not to mention a rise of 74.86% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HALO stock in for the last two-week period is set at 45.94, with the RSI for the last a single of trading hit 43.33, and the three-weeks RSI is set at 49.57 for Halozyme Therapeutics Inc. [HALO]. The present Moving Average for the last 50 days of trading for this stock 28.09, while it was recorded at 28.05 for the last single week of trading, and 22.29 for the last 200 days.

Insight into Halozyme Therapeutics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Halozyme Therapeutics Inc. [HALO] shares currently have an operating margin of -18.70 and a Gross Margin at +76.76. Halozyme Therapeutics Inc.’s Net Margin is presently recorded at -36.86.

Return on Total Capital for HALO is now -8.43, given the latest momentum, and Return on Invested Capital for the company is -19.05. Return on Equity for this stock declined to -42.41, with Return on Assets sitting at -14.36. When it comes to the capital structure of this company, Halozyme Therapeutics Inc. [HALO] has a Total Debt to Total Equity ratio set at 438.72. Additionally, HALO Total Debt to Total Capital is recorded at 81.44, with Total Debt to Total Assets ending up at 71.14. Long-Term Debt to Equity for the company is recorded at 417.42, with the Long-Term Debt to Total Capital now at 77.48.

Reflecting on the efficiency of the workforce at the company, Halozyme Therapeutics Inc. [HALO] managed to generate an average of -$547,273 per employee. Receivables Turnover for the company is 4.38 with a Total Asset Turnover recorded at a value of 0.39.Halozyme Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.30 and a Current Ratio set at 19.20.


With the latest financial reports released by the company, Halozyme Therapeutics Inc. posted -0.17/share EPS, while the average EPS was predicted by analysts to be reported at -0.12/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -41.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HALO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Halozyme Therapeutics Inc. go to 58.00%.

Halozyme Therapeutics Inc. [HALO] Insider Position Details

There are presently around $3,794 million, in the hands of institutional investors. The top three institutional holders of HALO stocks are: ARTISAN PARTNERS LIMITED PARTNERSHIP with ownership of 16,807,413, which is approximately 16.475% of the company’s market cap and around 1.10% of the total institutional ownership; BLACKROCK INC., holding 13,233,306 shares of the stock with an approximate value of $367.22 million in HALO stocks shares; and VANGUARD GROUP INC, currently with $362.07 million in HALO stock with ownership of nearly -6.12% of the company’s market capitalization.

Positions in Halozyme Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 170 institutional holders increased their position in Halozyme Therapeutics Inc. [NASDAQ:HALO] by around 17,657,093 shares. Additionally, 87 investors decreased positions by around 12,317,662 shares, while 27 investors held positions by with 106,744,735 shares. The mentioned changes placed institutional holdings at 136,719,490 shares, according to the latest SEC report filing. HALO stock had 75 new institutional investments in for a total of 5,322,119 shares, while 12 institutional investors sold positions of 634,008 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam